{"id":920,"date":"2025-06-04T01:57:22","date_gmt":"2025-06-04T08:57:22","guid":{"rendered":"https:\/\/cloudbreakpharma.com\/?p=920"},"modified":"2025-06-04T02:01:33","modified_gmt":"2025-06-04T09:01:33","slug":"cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial","status":"publish","type":"post","link":"https:\/\/cloudbreakpharma.com\/zh\/cloudbreak-pharmas-global-innovative-ophthalmic-pipeline-cbt-001-completes-the-enrollment-of-all-patients-in-the-international-multi-center-phase-iii-clinical-trial\/","title":{"rendered":"\u62e8\u5eb7\u89c6\u4e91\u5168\u7403\u521b\u65b0\u773c\u79d1\u836f\u7269CBT-001\u56fd\u9645\u591a\u4e2d\u5fc3III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u5b8c\u6210\u5168\u90e8\u60a3\u8005\u5165\u7ec4"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"920\" class=\"elementor elementor-920\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-c3fe21d elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"c3fe21d\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-74f661f\" data-id=\"74f661f\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-cf824e5 elementor-widget elementor-widget-text-editor\" data-id=\"cf824e5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Cloudbreak Pharma Inc.\uff08\u62e8\u5eb7\u89c6\u4e91\uff09\u6b23\u7136\u5ba3\u5e03\uff0c\u6211\u4eec\u7ba1\u7ebf\u4e2d\u7528\u4e8e\u6cbb\u7597\u7ffc\u72b6\u80ec\u8089\u7684\u5168\u7403\u521b\u65b0\u773c\u79d1\u836f\u7269CBT-001\u5f00\u5c55\u7684\u56fd\u9645\u591a\u4e2d\u5fc3III\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8fd1\u65e5\u5b8c\u6210\u4e86\u5168\u7403\u4e2d\u5fc3\u5168\u90e8\u60a3\u8005\u5165\u7ec4\u3002\u8be5\u7814\u7a76\u662f\u4e00\u9879\u968f\u673a\u3001\u53cc\u76f2\u3001\u5b89\u6170\u5242\u5e73\u884c\u5bf9\u7167\u7684III\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u62df\u5165\u7ec4660\u4f8b12\u5468\u5c81\u53ca\u4ee5\u4e0a\u7684\u7ffc\u72b6\u80ec\u8089\u4f34\u7ed3\u819c\u5145\u8840\u60a3\u8005\uff0c\u65e8\u5728\u8bc4\u4f30CBT-001\u6ef4\u773c\u6db2\u5728\u51cf\u5c11\u7ed3\u819c\u5145\u8840\u548c\u9884\u9632\u7ffc\u72b6\u80ec\u8089\u8fdb\u5c55\u65b9\u9762\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u3002<\/p><p>CBT-001\u7531Cloudbreak Pharma Inc.\uff08\u62e8\u5eb7\u89c6\u4e91\uff09\u5f00\u53d1\uff0c\u662f\u5df2\u4e0a\u5e02\u6cbb\u7597\u80ba\u7ea4\u7ef4\u5316\u836f\u7269OFEV\u7684\u4e3b\u8981\u6210\u5206\u5c3c\u8fbe\u5c3c\u5e03\u7684\u521b\u65b0\u6539\u826f\u4ea7\u54c1\uff0c\u5bf9\u65b0\u751f\u8840\u7ba1\u751f\u6210\u548c\u7ec4\u7ec7\u7ea4\u7ef4\u5316\u5747\u6709\u6291\u5236\u4f5c\u7528\u3002\u6b64\u524d\u5df2\u5728\u7f8e\u56fd\u5b8c\u6210II\u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u5b89\u5168\u6027\u9ad8\uff0c\u5177\u6709\u4e34\u5e8a\u7597\u6548\uff0c\u53ef\u6291\u5236\u7ffc\u72b6\u80ec\u8089\u751f\u957f\u5e76\u63a7\u5236\u75c5\u60c5\u8fdb\u5c55\u3002\u53ef\u7528\u4e8e\u7ffc\u72b6\u80ec\u8089\u8f7b\u4e2d\u91cd\u5ea6\u5404\u9636\u6bb5\uff0c\u53ca\u624b\u672f\u540e\u9632\u6b62\u590d\u53d1\u3002\u8fdc\u5927\u96c6\u56e2\u62e5\u6709CBT-001\u5728\u4e2d\u56fd\u5927\u9646\u3001\u4e2d\u56fd\u9999\u6e2f\u7279\u522b\u884c\u653f\u533a\u3001\u4e2d\u56fd\u6fb3\u95e8\u7279\u522b\u884c\u653f\u533a\u3001\u53ca\u4e2d\u56fd\u53f0\u6e7e\u5730\u533a\u7684\u72ec\u5bb6\u751f\u4ea7(\u542b\u6280\u672f\u8f6c\u79fb)\u53ca\u5546\u4e1a\u5316\u6743\u5229\uff0c\u6388\u6743\u8303\u56f4\u6db5\u76d6CBT-001\u7684\u5728\u7814\u9002\u5e94\u75c7\uff0c\u5373\u9884\u9632\u7ffc\u72b6\u80ec\u8089\u751f\u957f\u53ca\u51cf\u5c11\u7ed3\u819c\u5145\u8840\u3002\u62e8\u5eb7\u89c6\u4e91\u4ea6\u5c06CBT-001\u6388\u6743\u4e8e\u53c2\u5929\u5236\u836f\uff0c\u8be5\u6388\u6743\u6d89\u53ca\u65e5\u672c\u53ca\u97e9\u56fd\u3001\u8d8a\u5357\u3001\u6cf0\u56fd\u3001\u9a6c\u6765\u897f\u4e9a\u3001\u83f2\u5f8b\u5bbe\u3001\u65b0\u52a0\u5761\u548c\u5370\u5ea6\u5c3c\u897f\u4e9a\u5728\u5185\u7684\u4e1c\u5357\u4e9a\u5730\u533a\u3002\u6839\u636e\u534f\u8bae\u6761\u6b3e\uff0c\u62e8\u5eb7\u89c6\u4e91\u6388\u6743\u53c2\u5929\u5236\u836f\u5728\u8be5\u5730\u533a\u5f00\u53d1\u3001\u751f\u4ea7\u548c\u5546\u4e1a\u5316CBT-001\u836f\u54c1\u3002<\/p><p>\u7ffc\u72b6\u80ec\u8089\u662f\u4e00\u79cd\u5e38\u89c1\u7684\u6162\u6027\u708e\u75c7\u589e\u751f\u6027\u773c\u8868\u75be\u75c5\uff0c\u901a\u5e38\u53d1\u751f\u4e8e\u773c\u89d2\u90e8\u7ed3\u819c\uff0c\u9010\u6e10\u4fb5\u88ad\u81f3\u89d2\u819c\uff0c\u5f15\u8d77\u6563\u5149\u6216\u906e\u6321\u77b3\u5b54\uff0c\u4ece\u800c\u5bfc\u81f4\u89c6\u529b\u4e0b\u964d\u751a\u81f3\u81f4\u76f2\u3002\u636e\u4e16\u754c\u536b\u751f\u7ec4\u7ec7\u53d1\u5e03\u7684\u300a\u4e16\u754c\u89c6\u89c9\u62a5\u544a\u300b\u6240\u793a\uff0c\u7ffc\u72b6\u80ec\u8089\u7684\u5168\u7403\u60a3\u75c5\u7387\u4e3a10.2%\uff0c\u4e2d\u56fd\u519c\u6751\u5730\u533a\u9ad8\u8fbe33%\u3002\u6839\u636e\u76f8\u5173\u6587\u732e\uff0c\u4e2d\u56fd40\u5c81\u53ca\u4ee5\u4e0a\u4eba\u7fa4\u60a3\u75c5\u7387\u4e3a13.4%\uff0c\u4e14\u968f\u7740\u5e74\u9f84\u589e\u957f\u800c\u4e0d\u65ad\u5347\u9ad8\u3002\u76ee\u524d\u5e76\u6ca1\u6709\u6cbb\u7597\u7ffc\u72b6\u80ec\u8089\u7684\u4e13\u95e8\u836f\u7269\uff0c\u4e34\u5e8a\u4ee5\u4eba\u5de5\u6cea\u6db2\u3001\u975e\u753e\u4f53\u7c7b\u3001\u7cd6\u76ae\u8d28\u6fc0\u7d20\u6ef4\u773c\u6db2\u7b49\u6807\u7b7e\u5916\u7528\u836f\u4e3a\u4e3b\uff0c\u4f46\u73b0\u6709\u7684\u6cbb\u7597\u836f\u7269\u672a\u663e\u793a\u786e\u5207\u7597\u6548\u4e14\u5b58\u5728\u957f\u671f\u7528\u836f\u5b89\u5168\u6027\u98ce\u9669\u95ee\u9898\u3002\u4e25\u91cd\u60a3\u8005\u53ef\u901a\u8fc7\u624b\u672f\u6cbb\u7597\uff0c\u4f46\u7ffc\u72b6\u80ec\u8089\u91c7\u7528\u5de9\u819c\u5207\u9664\u672f\u540e\uff0c\u672f\u540e\u590d\u53d1\u7387\u4e3a30-80%\uff0c\u591a\u6b21\u590d\u53d1\u53ef\u9020\u6210\u7751\u7403\u7c98\u8fde\uff0c\u5f71\u54cd\u773c\u7403\u8fd0\u52a8\u3002\u53ef\u89c1\uff0c\u5bf9\u7ffc\u72b6\u80ec\u8089\u7684\u6cbb\u7597\u4ecd\u6709\u5de8\u5927\u7684\u4e34\u5e8a\u9700\u6c42\u672a\u83b7\u6ee1\u8db3\u3002<\/p><p>\u968f\u7740III\u671f\u4e34\u5e8a\u8bd5\u9a8c\u5168\u90e8\u60a3\u8005\u5165\u7ec4\u7684\u5b9e\u73b0\uff0cCBT-001\u5411\u7740\u6210\u4e3a\u5168\u7403\u9996\u4e2a\u7ffc\u72b6\u80ec\u8089\u4e13\u95e8\u6cbb\u7597\u836f\u7269\u7684\u76ee\u6807\u8fc8\u51fa\u4e86\u5173\u952e\u4e00\u6b65\u3002\u62e8\u5eb7\u89c6\u4e91\u5c06\u7ee7\u7eed\u5bc6\u5207\u5173\u6ce8\u8bd5\u9a8c\u8fdb\u5c55\uff0c\u786e\u4fdd\u7814\u7a76\u7684\u987a\u5229\u63a8\u8fdb\u3002\u6211\u4eec\u671f\u5f85\u8fd9\u9879\u521b\u65b0\u7597\u6cd5\u80fd\u591f\u65e9\u65e5\u5b8c\u6210\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u4e3a\u5168\u7403\u6570\u4ebf\u7ffc\u72b6\u80ec\u8089\u60a3\u8005\u5e26\u6765\u5b89\u5168\u6709\u6548\u7684\u6cbb\u7597\u9009\u62e9\uff0c\u586b\u8865\u8fd9\u4e00\u91cd\u8981\u533b\u7597\u9886\u57df\u7684\u7a7a\u767d\u3002\u540c\u65f6\uff0c\u901a\u8fc7\u4e0e\u8fdc\u5927\u96c6\u56e2\u548c\u53c2\u5929\u5236\u836f\u7684\u6218\u7565\u5408\u4f5c\uff0c\u6211\u4eec\u6709\u4fe1\u5fc3\u5c06\u8fd9\u4e00\u521b\u65b0\u6210\u679c\u60e0\u53ca\u4e9a\u592a\u5730\u533a\u5e7f\u5927\u60a3\u8005\uff0c\u4e3a\u6539\u5584\u5168\u7403\u773c\u5065\u5eb7\u505a\u51fa\u79ef\u6781\u8d21\u732e\u3002<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Cloudbreak Pharma Inc. is pleased to announce that our pipeline CBT-001, the global innovative ophthalmic drug for the treatment of pterygium has recently completed the enrollment of all patients in global centers in its international multicenter Phase III clinical trial. This study is a randomized, double-blind, placebo-controlled Phase III clinical trial, planning to enroll 660 [&hellip;]<\/p>\n","protected":false},"author":16,"featured_media":736,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-920","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts\/920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/comments?post=920"}],"version-history":[{"count":0,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/posts\/920\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/media\/736"}],"wp:attachment":[{"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/media?parent=920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/categories?post=920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cloudbreakpharma.com\/zh\/wp-json\/wp\/v2\/tags?post=920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}